Ultragenyx Pharmaceutical (RARE) Upgraded at BidaskClub

BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning.

Several other brokerages have also issued reports on RARE. ValuEngine upgraded Ultragenyx Pharmaceutical from a hold rating to a buy rating in a research report on Wednesday. Credit Suisse Group reaffirmed a hold rating and set a $59.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Raymond James lifted their price target on shares of Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the company a buy rating in a research note on Tuesday, November 6th. Canaccord Genuity decreased their price target on shares of Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a buy rating for the company in a research note on Wednesday, November 7th. Finally, Citigroup raised shares of Ultragenyx Pharmaceutical from a sell rating to a neutral rating and lifted their price target for the company from $46.00 to $54.00 in a research note on Thursday, November 8th. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $76.56.

Shares of NASDAQ:RARE opened at $59.82 on Wednesday. Ultragenyx Pharmaceutical has a 1 year low of $37.44 and a 1 year high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 35.26% and a negative net margin of 383.75%. The business had revenue of $16.26 million during the quarter, compared to analyst estimates of $13.30 million. On average, analysts anticipate that Ultragenyx Pharmaceutical will post -6.77 earnings per share for the current fiscal year.

In related news, Director William Aliski sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, December 7th. The shares were sold at an average price of $49.69, for a total value of $298,140.00. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at $3,607,990.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 8.40% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Capital Research Global Investors raised its stake in Ultragenyx Pharmaceutical by 1.7% in the third quarter. Capital Research Global Investors now owns 5,856,138 shares of the biopharmaceutical company’s stock worth $447,058,000 after buying an additional 100,575 shares in the last quarter. BlackRock Inc. raised its stake in Ultragenyx Pharmaceutical by 2.8% in the fourth quarter. BlackRock Inc. now owns 4,476,812 shares of the biopharmaceutical company’s stock worth $194,652,000 after buying an additional 123,409 shares in the last quarter. Capital International Investors raised its stake in Ultragenyx Pharmaceutical by 20.9% in the third quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock worth $332,834,000 after buying an additional 755,127 shares in the last quarter. Federated Investors Inc. PA raised its stake in Ultragenyx Pharmaceutical by 4.7% in the third quarter. Federated Investors Inc. PA now owns 1,484,271 shares of the biopharmaceutical company’s stock worth $113,309,000 after buying an additional 66,720 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in Ultragenyx Pharmaceutical by 16.5% in the fourth quarter. First Trust Advisors LP now owns 1,471,934 shares of the biopharmaceutical company’s stock worth $64,000,000 after buying an additional 208,468 shares in the last quarter. 98.35% of the stock is owned by institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Further Reading: NASDAQ Stock Market Explained

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit